University of Colorado, Denver
The goal of this observational study is to determine whether circulating tumor DNA (ctDNA) clearance at the completion of chemoradiotherapy (chemotherapy and radiation therapy) can predict durable complete response in adults with localized esophageal squamous cell carcinoma (ESCC). ctDNA clearance refers to the disappearance of detectable tumor DNA from the blood after treatment. Current methods used to assess treatment response, including imaging scans (PET/CT) and endoscopy, have limitations in reliably identifying patients who achieve a durable complete response after chemoradiotherapy. Researchers will evaluate whether ctDNA clearance improves the prediction of durable complete response beyond standard response assessments. The findings may help identify patients suitable for non-operative management with active surveillance. The main questions this study aims to answer are: * Can ctDNA clearance after chemoradiotherapy predict 2-year complete response-disease-free survival? * Can ctDNA clearance improve the prediction of durable complete response compared with standard response assessment methods, including PET/CT and endoscopy? * Can ctDNA clearance at different timepoints during and after chemoradiotherapy help identify patients at risk of disease recurrence? The study will enroll approximately 120 adults with localized esophageal squamous cell carcinoma undergoing curative-intent chemoradiotherapy as part of standard clinical care. Study participants will: * Provide blood samples at baseline, during Week 3 of chemoradiotherapy, and at completion of chemoradiotherapy for ctDNA analysis. * Participate in one of two observational cohorts. Participants in the Longitudinal ctDNA Cohort will provide additional blood samples at 6 weeks and 3 months after chemoradiotherapy and every 3 months through 24 months. Participants in the Limited-Sampling Research Cohort will provide only three protocol-required blood samples. * Continue standard-of-care cancer treatment and follow-up according to treating physician discretion. * Allow researchers to review medical records to assess treatment response, cancer recurrence, salvage therapy, and survival status through 24 months after completion of chemoradiotherapy. Researchers will compare ctDNA results with standard clinical response assessments, including PET/CT and endoscopy, and clinical outcomes. Researchers will also assess whether ctDNA results influence physician treatment recommendations and clinical decision-making in the Longitudinal ctDNA Cohort. This observational study does not involve investigational therapeutic interventions or require changes to standard clinical management. The findings may help improve risk stratification and identify patients suitable for organ-preservation strategies or closer surveillance following chemoradiotherapy.
Inclusion Criteria: * Provision to sign and date the consent form. * Stated willingness to comply with all study procedures and be available for the duration of the study. * Age ≥18 years. * Histologically confirmed cervical or thoracic esophageal squamous cell carcinoma (ESCC). For cervical tumors (defined per NCCN as \<5 cm from cricopharyngeus), the primary site must be the cervical esophagus rather than a primary hypopharyngeal malignancy as determined by the treating multidisciplinary team. * Clinical stage cT1-4 or cTX, N0-3, M0 disease according to AJCC 8th Edition staging, based on av…
Peripheral blood samples are collected for tumor-informed circulating tumor DNA (ctDNA) assessment using the Signatera™ Genome Assay. ctDNA testing is performed at protocol-defined time points to evaluate ctDNA clearance and kinetics in participants with localized esophageal squamous cell carcinoma undergoing standard-of-care chemoradiotherapy. Results are returned through routine clinical workflows; no protocol-mandated treatment modifications are required based on ctDNA results.